Techno Trends

Techno Trends includes advancements and innovations in pharmaceutical products and technology from around the world. Additionally, you may keep abreast of any recent advancements in the pharmaceutical industry (product information and technological trends).

Celltrion Secures FDA Approval for OMLYCLO® 300 mg, First Interchangeable Biosimilar to XOLAIR

Celltrion has announced U.S. FDA approval of a new 300 mg/2 mL prefilled syringe presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab)....

Imfinzi Gains U.S. Approval as First Perioperative Immunotherapy for Early Gastric Cancers

AstraZeneca’s Imfinzi (durvalumab), combined with FLOT chemotherapy, has been approved in the United States for adults with resectable early-stage and locally advanced gastric and gastroesophageal junction cancers....

UCB Secures FDA Approval for First Ever TK2 Deficiency (TK2d) Therapy

UCB has gained approval from the U.S. Food and Drug Administration for KYGEVVI™ (doxecitine and doxribtimine) to treat thymidine kinase 2 deficiency (TK2d) in adults and children whose symptoms began at age 12 or younger. ...

Amneal Launches Brekiya®, First and Only DHE Autoinjector for Migraine and Cluster Headaches

Amneal Pharmaceuticals, Inc. has launched Brekiya® (dihydroergotamine mesylate) injection in the United States, the first and only ready-to-use DHE autoinjector approved for the acute treatment...

FDA Grants Breakthrough Therapy Status to Zenocutuzumab-zbco for NRG1+ Cancer

Partner Therapeutics, Inc. (PTx) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to zenocutuzumab-zbco for the treatment of adults with advanced unresectable...

Lundbeck’s Bexicaserin Receives Breakthrough Therapy Designation for Severe Epilepsies

Lundbeck has announced that its investigational drug bexicaserin has been granted Breakthrough Therapy Designation (BTD) by China’s Center for Drug Evaluation (CDE) for the treatment of seizures associated...

FDA Grants Breakthrough Therapy Status to Cidara’s CD388 for Influenza Prevention

Cidara Therapeutics, Inc. received Breakthrough Therapy designation by the U.S. Food and Drug Administration for CD388, a long-acting treatment aimed at preventing influenza A and B. ...

HKU Scientists Develops Groundbreaking Drug Against Every Known Coronavirus

Researchers from the University of Hong Kong’s LKS Faculty of Medicine (HKUMed) and the InnoHK Centre for Virology, Vaccinology and Therapeutics (CVVT), in collaboration with Sichuan University, have developed a new antiviral compound...